European Medicines Agency’s panel recommends expanding Amgen’s Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates.
EMA Backs Amgen Drug For Rare Autoimmune Disorder
Where Today's News Shapes Tomorrow
